WuXi STA
About WuXi STA
Categories
-
US
-
2015On CPHI since
-
5000+Employees
Company types
Meet us at
CPHI North America 2024
Pennsylvania Convention Center, Philadelphia
07 May 2024 - 09 May 2024
CPHI Milan 2024
Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
Products from WuXi STA (5)
-
Product Pre-formulation development
WuXi STA's IND Enabling Preformulation Package (IEPP) is an integrated end-to-end developability assessment service for new chemical entities (NCE). Efficiently identify challenges and solutions earlier for higher success rates and lower overall costs. PK formulation, Profiling, Form selection, and&nb... -
Product Bioavailability enhancement and advanced delivery technologies
Bioavailability Toolbox:Spray-dried dispersion (SDD) - preclinical to commercial scale
Hot melt extrusion (HME)
Nano suspension
Softgel & Liquid filled capsules
Injectable -
Product Peptide Process Development and Manufacturing
WuXi STA Peptide platform services include: Process R&D, Manufacturing grams to kilograms peptides under cGMP, Analytical characterization, method development and validation, IPC & release testing, ICH compliant stability studies, Regulatory (CMC) submission support. Our platform support a wide var... -
Product Oligonucleotide Process Development and Manufacturing
WuXi STA has an integrated Oligo API process R&D and manufacturing platform from preclinical to commercial, operating at our US FDA inspected integrated process R&D and manufacturing facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modal... -
Product Highly potent API and ADC payload and payload-linker manufacturing
WuXi STA's Jinshan site and WuXi STA's Changzhou site are equipped with a R&D labs, a cGMP HP Kilo lab, and cGMP plant for handling highly potent APIs (HPAPIs) and antibody drug conjugate (ADC) payloads and payload-linkers. We offer drug product manufacturing at STA’s Shanghai Waiga...
WuXi STA Resources (4)
-
News New drug product service delivers expedited CTM
Biotech and pharma innovators are facing considerable challenges to find CDMO partners with capacity and capability to quickly develop and deliver high-quality CTM with flexible options+ -
Sponsored Content End game strategies to reach patients globally and swiftly
The journey for new therapies is long; wondering if a proven therapy will be produced and distributed efficiently to reach the intended markets as soon as possible should not be another burden -
News Hoth Therapeutics and WuXi strike API and drug product deal for cancer therapeutic
WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance